ARTVArtiva Biotherapeutics, Inc.
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Rangebound, no clear trend. Oversold (RSI 25). Price is −14% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ARTV is trading
Artiva Biotherapeutics, Inc. is +135% over the past year while the S&P 500 is +18%: 117 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −14%
vs 200-day average · a clear downtrend
- RSI (14)
- 25
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 49%
Below its 52-week high
Details›
- Last close2026-10-08
- $6.81
- 1 monthS&P 500 +1.6%
- −37%
- 1 yearS&P 500 +18%
- +135%
- vs 50-day average$9.87
- −31%
- 52-week high
- $13.39
- 52-week low
- $2.74
- Annualised volatility
- 155%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $104M
| Year | Return |
|---|---|
| 2026 (year to date) | +59% |
| 2025 | −57% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 0 of 2 | −29% |
| Feb | 2 | 1 of 2 | +16% |
| Mar | 2 | 1 of 2 | −8.5% |
| Apr | 2 | 1 of 2 | +19% |
| May | 2 | 0 of 2 | −21% |
| Jun | 2 | 1 of 2 | +0.22% |
| Jul | 2 | 2 of 2 | +51% |
| Aug | 3 | 2 of 3 | +5.1% |
| Sep | 3 | 1 of 3 | −4.1% |
| Oct | 3 | 1 of 3 | +2.2% |
| Nov | 2 | 1 of 2 | +8.1% |
| Dec | 2 | 1 of 2 | −3.5% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry